Dr. Raanani reflects on caring for hem/onc patients amid war in Israel
Pia Raanani, MD, head of the Institute of Hematology at the Davidoff Cancer Center at the Rabin Medical Center in Israel, shared her
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Leukemia
Video Interviews
Society Updates
Myelodysplastic Syndromes
Dr. Garcia-Manero discusses mature data on luspatercept’s efficacy in MDS
Guillermo Garcia-Manero MD, of the University of Texas MD Anderson Cancer Center, discusses long-term data from the COMMANDS trial, highlighting the use of
Leukemia
News
Society Updates
Ask Dr. Kantarjian your leukemia questions
Do you have a question about the treatment or management of leukemias? Submit your question in our new forum in the SOHO mobile
Lymphoma
Mantle Cell Lymphoma
News
FDA approves acalabrutinib plus chemoimmunotherapy in previously untreated MCL
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has been approved in the United States in combination with bendamustine and rituximab for the treatment
Leukemia
Chronic Myeloid Leukemia
IND approved in Korea for CML treatment KF1601
An Investigational New Drug (IND) application for KF1601, a chronic myeloid leukemia (CML) treatment was submitted to and approved by the Korea Ministry
Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndromes
News
FDA grants fast track designation to LYT-200 in AML
The US Food and Drug Administration (FDA) has granted fast track designation to LYT-200 for the treatment of acute myeloid leukemia (AML). LYT-200
Cellular Therapy
Lymphoma
CAR-NK cell therapy FT596 ‘well tolerated’ in phase 1 trial
FT596, a CD19-directed chimeric antigen receptor (CAR) natural killer (NK) cell therapy, was well tolerated in patients with relapsed or refractory B-cell lymphoma
66th American Society of Hematology Annual Meeting & Exposition
Myeloma
News
Video Interviews
Refining progression criteria in relapsed myeloma
Jean-Sébastien Claveau, MD, of Maisonneuve-Rosemont Hospital at the University of Montreal, spoke with SOHO Insider at the 66th American Society of Hematology Annual
Cellular Therapy
Multiple Myeloma
News
Do older patients with myeloma respond as well to ide-cel as younger patients?
“[T]hese findings provide reassurance that older adults treated with ide-cel, including frail patients, experience comparable efficacy to younger patients,” the authors wrote.
Multiple Myeloma
News
Society Updates
Message from Editor-in-Chief Dr. Lonial: Advancing care amid uncertainty
May you live in interesting times…. You may have encountered this adage at some point in your life, though its origins are difficult